Cadila Healthcare said on Thursday that Zydus had received the final approval from the US FDA to market Imatinib Mesylate tablets, a drug used in the treatment of leukaemia, bone marrow disorders, skin cancers and tumours of the stomach.
The company informed that the drug would be manufactured at the group's formulation manufacturing facility in Ahmedabad.
The shares rose as much as 7 per cent to Rs 374 in early trade. It is currently trading 2.17 per cent higher at Rs 357.45.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.